Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study.

Baskin, Esra; Fidan, HATİCE; GÜLHAN, BORA; Gulleroglu, Kaan; CANPOLAT, NUR; Yilmaz, Alev; Parmakiz, Gonul; ÖZÇAKAR, ZEYNEP; ÖZALTIN, FATİH; Soylemezoglu, HÜSNÜ

doi:10.1007/s40620-021-01212-w

Eculizumab treatment and discontinuation in pediatric patients with atypical hemolytic uremic syndrome: a multicentric retrospective study.

Atıf İçin Kopyala

Baskin E., Fidan K., GÜLHAN B., Gulleroglu K., CANPOLAT N., Yilmaz A., ...Daha Fazla

Journal of nephrology, cilt.35, sa.4, ss.1213-1222, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 35 Sayı: 4
Basım Tarihi: 2022
Doi Numarası: 10.1007/s40620-021-01212-w
Dergi Adı: Journal of nephrology
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.1213-1222
Anahtar Kelimeler: Eculizumab treatment, Pediatric patient, Atypical hemolytic uremic syndrome, Eculizumab discontinuation
Gazi Üniversitesi Adresli: Evet

Özet

Introduction Eculizumab is effective treatment of pediatric atypical hemolytic uremic syndrome (aHUS). However, the optimal duration of treatment is not clearly defined. The aim of this study was to retrospectively analyze the outcome of pediatric patients with aHUS, who started eculizumab treatment but discontinued it during the follow-up period.